Preventing low platelets from chemo in GI cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Digestive system clinical trials.
This trial tests if hetrombopag can prevent low platelet counts caused by chemotherapy in people with gastrointestinal cancers. It may help reduce the risk of bleeding and the need for platelet transfusions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a GI cancer like esophageal, stomach, or colorectal cancer.
- You had a platelet count of at least 75 in your last chemo cycle AND had a bleeding risk factor (like past bleeding, certain chemo drugs, bone marrow involvement, or radiation).
- Your platelet count is at least 100 before starting a new chemo cycle.
- You are on a 14- or 21-day chemo cycle and need at least one more cycle.
- You have adequate kidney, liver, and blood cell function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medicine called romiplostim N01 to see if it can prevent low platelet counts caused by chemotherapy in breast cancer patients. It may help reduce the risk of bleeding and allow you to complete your chemotherapy on time.
This study tests an investigational pill (hetrombopag) to see if it can safely raise platelet counts in people with solid tumors whose platelets drop after chemotherapy. If you are receiving platinum- or gemcitabine-based chemo and have low platelets due to chemo, this trial may be an option.
This study tests a medication called eltrombopag to help prevent dangerously low platelet counts (blood cells that help clotting) in breast cancer patients receiving chemotherapy. Low platelets can cause bleeding problems, and this drug may help keep your counts safer during treatment.
This trial tests a drug called Hetrombopag to see if it can prevent low platelet counts in people with advanced lung cancer who are receiving certain types of chemotherapy. The goal is to help keep platelet levels safe so you can continue your cancer treatment without delays or dose reductions.
This trial tests if Hetrombopag can prevent low blood platelets caused by gemcitabine and cisplatin chemotherapy for nasopharyngeal carcinoma. It may help patients who had low platelets in a previous chemo cycle.
This trial tests a drug called hetrombopag to help raise platelet counts in women whose cancer therapy has caused low platelets. The goal is to see if it can safely prevent the need for platelet transfusions.
Hear when a new Chemotherapy-induced Thrombocytopenia (CIT) in Patients With Gastrointestinal Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.